David Bonita
SlowingNamed in filings at Orbimed PartnersOn the current fund
- Board seats filed
- 13
- Named on a board
- 1
all filings on record
Named in filings at Orbimed PartnersOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Thrombolex | Medical devices | February 2026 | Orbimed New Horizons |
| Ikena Oncology | Biotech & pharma | August 2023 | Atlas Venture, Orbimed New Horizons |
| Adela | Biotech & pharma | July 2021 | Orbimed New Horizons |
| Treeline Biosciences | Biotech & pharma | April 2021 | ARCH Venture Partners, Orbimed New Horizons |
| IMARA | Biotech & pharma | March 2019 | New Enterprise Associates, Orbimed New Horizons |
| SI-BONE | Medical devices | June 2016 | Orbimed New Horizons |
| Prelude Therapeutics | Biotech & pharma | June 2016 | Orbimed New Horizons |
| Acutus Medical | Medical devices | March 2016 | Orbimed New Horizons |
| ViewRay | Medical devices | July 2015 | Orbimed New Horizons |
| Clementia Pharmaceuticals | Biotech & pharma | June 2015 | Orbimed New Horizons |
| Tricida | Biotech & pharma | February 2015 | Orbimed New Horizons |
| Loxo Oncology | Biotech & pharma | April 2014 | Orbimed New Horizons |
| VIEWRAY | Medical devices | March 2012 | Orbimed New Horizons |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name David Bonita on the board, based on 13 filed seats with a verified or cited source.